非选择性beta受体阻滞剂治疗肝硬化门脉高压症患者研究进展  

Administration of non-selective beta-blockers in treatment of patients with liver cirrhosis and portal hypertension

作　　者：吴玲(综述) 李锋(审校) Wu Ling;Li Feng(Department of Gastroenterology and Hepatology,Zhongshan Hospital,Fudan University,Shanghai 200032,China)

机构地区：[1]复旦大学附属中山医院消化科,上海市200032

出　　处：《实用肝脏病杂志》2022年第1期144-147,共4页Journal of Practical Hepatology

基　　金：国家自然科学基金资助项目(编号:8127007/81670513);上海市人才发展资金资助项目(编号:201304);上海市青年科技启明星计划资助项目(编号:13QA1400700);上海市卫生计生系统优秀青年医学人才培养计划项目(编号:13YO56)。

摘　　要：目的肝硬化是各种慢性肝病进展后的病理学阶段,失代偿期常以肝功能减退和门脉高压症为主要临床表现。非选择性β受体阻滞剂(NSBB)可有效降低门脉压力,是近30年来治疗肝硬化门脉高压症的主要方法之一。然而,NSBB改变血流动力学的作用常对患者的循环功能造成影响,是否应用NSBB及其用法用量需因人而异。本文综述了肝硬化患者合理应用NSBB及其争议问题的讨论。Objective The liver cirrhosis(LC)is the consequence of various chronic liver diseases,with liver function abnormality and portal hypertension occurring in the decompensatory stage.The non-selective beta-blockers(NSBB)has been one of the main medicine for patients with portal hypertension in almost 3 decades,inasmuch as its capacity in reducing portal pressure,though,at the same time,the hemodynamic effects of NSBB can influence the circulatory function of patients.When and how to prescribe NSBB depends on patients’conditions.We aimed to review the reasonable application and controversy of NSBB treatment in cirrhotic patients.

关 键 词：肝硬化 门脉高压症 非选择性Β受体阻滞剂 

分 类 号：R57[医药卫生—消化系统]